Loading
ZI
Zynex Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 30 Jul 2024.
Zynex Inc: what insiders have been doing
This page follows insider dealings at Zynex Inc as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in Englewood, United States. The group dates from 2001. From 18 October 2025 to 18 October 2026, the disclosure feed for Zynex Inc logged 3 filings by 3 insiders.
Not one of the filings records a straightforward purchase or sale on the market. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
For context, the typical company on the same exchange (median of 5,813 companies) published 19 filings over the same period, against 3 filings here. Looking back to 2021, when coverage begins, insiders filed 1 purchase and 15 sales.
There has been no open-market purchase by an insider of Zynex Inc for at least a year. Typically, a trade is published a median of 1 day after it takes place. For comparison, the SEC allows two business days to file a Form 4.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
179
Thresholds
n/a
Buy Volume
€53,822
1 ops. · all time
Sell Volume
€3M
15 ops. · all time
Who traded when
BuySaleDaniel J. Moorhead5 sales
Thomas Sandgaard3 sales
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended December 2024 · cache
Income statement
RevenueUS$165.6M
Gross profitUS$11.7M7% margin
Net incomeUS$2.6M1.6% margin
Last declaration on 27 March 2026
Declarations179 total
12,499 shares0Common Stock (Restricted Stock Award)SEC:0001745117-26-000002:0
12,499 shares0Common Stock (Restricted Stock Award)SEC:0001566240-26-000002:0
80,001 shares0Common StockSEC:0001162525-26-000002:0
7,500 shares0Common Stock (Restricted Stock Award)SEC:0001415889-25-020510:0
3,982 shares@ US$2.130.8% of flowCommon StockSEC:0001415889-25-016070:0
10,000 shares0Common Stock (Restricted Stock Award)SEC:0001415889-25-013481:0
10,000 shares0Common Stock (Restricted Stock Award)SEC:0001415889-25-013482:0
10,000 shares0Common Stock (Restricted Stock Award)SEC:0001415889-25-013480:0
7,500 shares0Common Stock (Restricted Stock Award)SEC:0001415889-25-011547:0
1,700,000 shares@ US$2.90537.7% of flowCommon StockSEC:0001104659-25-024556:0
10,000 shares@ US$7.157.4% of flowCommon StockSEC:0001415889-25-007098:0
10,000 shares@ US$7.688.1% of flowCommon StockSEC:0001415889-25-002804:0
7,500 shares0Common Stock (Restricted Stock Award)SEC:0001415889-25-002296:0
10,000 shares@ US$7.888.2% of flowCommon StockSEC:0001415889-25-000658:0
5,000 shares0Common Stock (Restricted Stock Award)SEC:0001415889-24-028557:0
10,000 shares@ US$8.088.3% of flowCommon StockSEC:0001415889-24-028194:0
2,000 shares@ US$8.090.1% of flowCommon StockSEC:0001415889-24-027128:0
2,000 shares@ US$9.170.1% of flowCommon StockSEC:0001415889-24-026751:0
2,000 shares@ US$8.670.1% of flowCommon StockSEC:0001415889-24-026282:0
10,000 shares@ US$8.598.5% of flowCommon StockSEC:0001415889-24-026049:0
2,000 shares@ US$8.920.1% of flowCommon StockSEC:0001415889-24-025931:0
6,912 shares0Common Stock (Restricted Stock Award)SEC:0001415889-24-025705:0
5,000 shares0Common Stock (Restricted Stock Award)SEC:0001415889-24-025704:0
6,912 shares0Common Stock (Restricted Stock Award)SEC:0001415889-24-025706:0
5,000 shares0Common Stock (Restricted Stock Award)SEC:0001415889-24-022975:0
25 of 179 declarations
About Zynex Inc
Zynex Inc. (ticker: ZYXI) is a U.S. medical-device company that has been listed on the NASDAQ market in the United States. Headquartered in Englewood, Colorado, the company was founded in 1996 by Thomas Sandgaard. Its core franchise has historically focused on electrotherapy and pain-management solutions, serving patients and healthcare providers primarily in the United States and, more broadly, North America. ([sec.gov](https://www.sec.gov/Archives/edgar/data/846475/000155837025002717/zyxi-20241231x10k.htm?utm_source=openai))
The company’s main operating business is Zynex Medical, which designs, manufactures, and markets devices used to treat acute and chronic pain and to activate and rehabilitate muscles through electrical stimulation. Its commercial portfolio includes devices such as TENS, IFC, and NMES systems, sold or leased alongside recurring consumables, as well as complementary rehabilitation products including cervical and lumbar traction, knee braces, wrist supports, and hot/cold therapy products. That mix of device sales and recurring supply revenue is an important feature of the model, as growth in the installed base can support follow-on consumable demand. ([sec.gov](https://www.sec.gov/Archives/edgar/data/846475/000155837025009557/zyxi-20241231x10ka.htm?utm_source=openai))
Read moreShow less
Zynex also operates Zynex Monitoring Solutions (ZMS), a smaller and more developmental segment focused on non-invasive monitoring technologies. SEC filings indicate that ZMS developed a fluid-monitoring system that received initial FDA approval in the U.S., and the company has also pursued European regulatory pathways. More recently, the company disclosed a strategic reset of this business, including a major workforce reduction at ZMS to capture cost savings, underscoring that monitoring remains an option value asset rather than a mature earnings driver. ([sec.gov](https://www.sec.gov/Archives/edgar/data/846475/000155837025002717/zyxi-20241231x10k.htm?utm_source=openai))
From a competitive standpoint, Zynex is a niche player in non-invasive pain treatment and rehabilitation rather than a broad diversified medtech platform. Its positioning depends on physician relationships, sales-force execution, reimbursement access, and the breadth of its home-use therapy offering. The company has stated that substantially all of its revenue has come from North America, so its geographic footprint remains concentrated and comparatively limited internationally. ([sec.gov](https://www.sec.gov/Archives/edgar/data/846475/000155837025009557/zyxi-20241231x10ka.htm?utm_source=openai))
Recent developments are highly material for investors. During 2025, Zynex reported weaker order trends, lower supplies revenue, a trimmed sales force, and pressure from temporary Tricare reimbursement issues. The company also disclosed a restructuring of ZMS. Most importantly, on December 15, 2025, Zynex and certain subsidiaries filed voluntary Chapter 11 petitions in the United States, after which Nasdaq suspended trading of the common stock and the shares were moved to the Pink Limited Market in late December 2025. For equity investors, that means Zynex should be viewed as a distressed turnaround case with significant operational, reimbursement, and balance-sheet risk. ([sec.gov](https://www.sec.gov/Archives/edgar/data/846475/000110465925121390/zyxi-20251215x8k.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
